Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed
- Conditions
- Squamous Cell Carcinoma
- Interventions
- Drug: Aldoxorubicin HClBiological: ETBX-011Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNK for infusionDrug: AvelumabDrug: bevacizumabDrug: CapecitabineDrug: CetuximabDrug: CisplatinDrug: CyclophosphamideDrug: FluorouracilDrug: LeucovorinDrug: nab-PaclitaxelDrug: NecitumumabProcedure: SBRTBiological: N-803
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT03387111
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Drug: Aldoxorubicin HClBiological: N-803Biological: ETBX-011Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNK for InfusionBiological: avelumabBiological: bevacizumabDrug: CapecitabineDrug: CisplatinDrug: CyclophosphamideDrug: 5-FluorouracilDrug: LeucovorinDrug: nab-PaclitaxelProcedure: SBRT
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT03387085
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
- Conditions
- Pancreatic Cancer
- Interventions
- Drug: Aldoxorubicin HClBiological: ALT-803Biological: ETBX-011Biological: GI-4000Biological: haNK for infusionBiological: avelumabBiological: bevacizumabDrug: CapecitabineDrug: CyclophosphamideDrug: FluorouracilDrug: LeucovorinDrug: nab-PaclitaxelDrug: lovazaDrug: OxaliplatinProcedure: SBRT
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT03387098
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab
- Conditions
- Acquired Hemophilia A
- Interventions
- First Posted Date
- 2017-12-27
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Zhang Lei, MD
- Target Recruit Count
- 66
- Registration Number
- NCT03384277
- Locations
- 🇨🇳
Ethics Committee of Blood disease hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Conditions
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Interventions
- First Posted Date
- 2017-12-27
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 47
- Registration Number
- NCT03384654
- Locations
- 🇺🇸
Children'S Healthcare Of Atlanta/Emory Univ. Dept. Of Pediatrics, Atlanta, Georgia, United States
🇺🇸Newark Beth Israel Medical Center, Newark, New Jersey, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma
- Conditions
- Refractory or Relapsed Multiple Myeloma
- Interventions
- First Posted Date
- 2017-12-20
- Last Posted Date
- 2020-10-12
- Lead Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 6
- Registration Number
- NCT03380039
- Locations
- 🇨🇳
Xin Hua Hospital of Shanghai Jiao Tong University of Medicine, Shanghai, Shanghai, China
Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer
- Conditions
- Breast CancerEndocrine Breast DiseasesChemotherapy
- Interventions
- First Posted Date
- 2017-12-14
- Last Posted Date
- 2017-12-18
- Lead Sponsor
- Zhiyong Yu
- Target Recruit Count
- 200
- Registration Number
- NCT03373708
Induction Therapy With Anti-TNFα vs Cyclophosphamide in Severe Behçet Disease
- Conditions
- VasculitisBehcet's Disease
- Interventions
- First Posted Date
- 2017-12-13
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 53
- Registration Number
- NCT03371095
- Locations
- 🇫🇷
CHRU Amiens, Amiens, France
🇫🇷CHU Bordeaux, Bordeaux, France
🇫🇷Hôpital Saint André, Bordeaux, France
Anti T-lymphocyte Immunoglobulin With Post Transplant Cyclophosphamide to Prevent GVHD Post Allogeneic Transplantation
- Conditions
- Graft Versus Host Disease
- Interventions
- Drug: CyclophosphamideDrug: anti-human T-lymphocyte immunoglobulin (ATLG)
- First Posted Date
- 2017-11-29
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT03357159
- Locations
- 🇮🇱
Chaim Sheba Medical Center, Ramat Gan, Israel
Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.
- Conditions
- Breast CancerLuminal BTriple Negative Breast Cancer
- Interventions
- First Posted Date
- 2017-11-29
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Grand Hôpital de Charleroi
- Target Recruit Count
- 57
- Registration Number
- NCT03356860
- Locations
- 🇧🇪
Grand Hôpital de Charleroi, Charleroi, Hainaut, Belgium
🇧🇪CHU UCL Namur - Sainte-Elisabeth, Namur, Région Wallonne, Belgium
🇧🇪CHU UCL Namur - Site Godinne, Yvoir, Région Wallonne, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.